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Abstract
Background: rs1333049 polymorphism on chromo-
some 9p21 has been shown to affect susceptibility to
coronary artery disease (CAD) in Caucasians. This
study examined the association of rs1333049 with
myocardial infarction (MI), angiographic severity of
CAD and clinical outcome after a first acute MI in Han
Chinese.
Methods: rs1333049 polymorphism was genotyped in
520 patients with a first acute MI and in 560 controls.
The number of angiographically documented dis-
eased coronary arteries (luminal diameter stenosis
G50%), echocardiographic left ventricular ejection
fraction (LVEF), and major adverse cardiac events
(MACE) during follow-up (mean, 29"15 months) were
recorded.
Results: Patients with MI had higher frequencies of
the CC genotype (30.0% vs. 20.7%) or C allele (55.5%
vs. 46.2%) compared with controls (all p-0.01).
rs1333049 polymorphism was strongly associated
with MI wodds ratio (OR) 1.48, 95% confidence interval
(CI) 1.22–1.79x after adjusting for traditional risk fac-
tors. Although longer hospitalization stay was
observed in patients with the rs1333049-C allele, this
polymorphism was not related to angiographic sever-
ity of CAD, LVEF, and occurrence of MACE after MI.
Conclusions: This study demonstrates an association
of rs1333049 polymorphism locus on chromosome
9p21 with risk for MI, but not with post-MI prognosis
in Han Chinese.
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Introduction
It is widely accepted that genetic variation is impor-
tant for the pathogenesis of coronary artery disease
(CAD), myocardial infarction (MI) and clinical outcome
(1, 2). Although numerous candidate genes have been
implicated in the development and progression of
atherosclerosis, the genes that are responsible
remain largely unknown. Recently, genome-wide
association studies have demonstrated a locus on
chromosome 9p21 for CAD susceptibility in Cauca-
sians (3–7). Chromosome 9p21 was found to also be
associated with other atherosclerotic diseases such as
stroke and aneurysm (8–10).
Studies on chromosome 9p21 were performed pri-
marily in Caucasians, while similar studies in Asians
are less common (7). As variants and their frequen-
cies of chromosome 9p21 in various ethnic groups
might be different, replication is needed to confirm
the potential effects of chromosome 9p21 in other
groups. In addition, genetic factors implicated in ath-
erogenesis may affect the outcome of cardiovascular
disease. However, little data is available regarding the
impact of chromosome 9p21 on the prognosis of
Asian patients with CAD. The present study was con-
ducted to assess the association of rs1333049 poly-
morphism, one representative polymorphism on
chromosome 9p21 (7), with MI, angiographic severity
of CAD, and occurrence of major adverse cardiac
events (MACE) after acute MI in Han Chinese.
Materials and methods
Study population
The study protocol was approved by the Hospitals Ethics
Committee. All participants were of Chinese Han origin and
gave written informed consent. There were 584 patients
included in this study who survived a first acute ST-segment
elevation MI between November 2003 and December 2006.
MI was defined as 1) ischemic chest pain of )30 min dura-
tion not relieved by sublingual nitrates, 2) new ST-segment
elevation in at least two contiguous leads of 12-lead electro-
cardiogram, with the cut-off points G0.2 mV, 3) new, or pre-
sumably new, left bundle branch block (LBBB), 4) increased
serum creatine kinase MB and troponin T at least 2 times
greater than the upper limit of the reference interval. To
avoid confounding results, patients with concomitant severe
kidney disease (12 patients), liver disease (13 patients),
malignancy (2 patients), valvular disease (19 patients) and
cardiomyopathy (3 patients) were excluded. Fifteen patients
lost to follow-up were also excluded leaving 520 patients for
inclusion in the analysis.
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The control subjects were residents of three major districts
in Shanghai who received an annual physical examination
in 2005. A detailed medical and family history was obtained;
none had documented CAD, severe kidney or liver disease,
or malignancy. The control subjects were selected to match
MI patients with respect to age, gender, and traditional risk
factors such as smoking, diabetes and hypertension, without
knowledge of chromosome 9p21 genotypes.
Coronary angiography was performed using standard
Judkins technique or radial approach. Severity of CAD was
defined according to the total number of significant stenotic
coronary arteries (luminal diameter narrowing G50%). Cor-
onary lesion types (A, B1, B2, or C) were defined according
to a modified classification of the American College of
Cardiology/ American Heart Association (11).
Two-dimensional echocardiography was performed at
discharge using Vivid-7 system (GE Vingmed Sound AS,
Horton, Norway). Left ventricular ejection fraction (LVEF)
was determined using apical four chamber view by Sim-
pson’s method.
Patients with MI received clinical follow-up in a special
outpatient clinic or were contacted by telephone every
3 months after initial angiography (mean, 29"15 months).
Occurrence of MACE included cardiac death, recurrence of
non-fatal MI, recurrent angina or heart failure requiring hos-
pitalization. In order to guarantee quality of the data, cause
of death was verified by reviewing hospital records and
death certificates. All MACE were reviewed by two experi-
enced interventional cardiologists.
Blood samples were collected after an overnight fast at
hospital admission and stored at –808C. White blood cell
count, serum glucose, creatinine, and lipid profiles wtotal
cholesterol, low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), lipoprotein (a),
apolipoprotein A (apoA), apolipoprotein B (apoB) and tri-
glyceridesx were measured (HITACHI 912 Analyzer, Roche
Diagnostics, Germany).
Genotype determination
Whole blood was drawn from each participant and genomic
DNA was extracted from peripheral blood leucocytes using
standard phenol-chloroform extraction. Genotyping was
performed with TaqMan single nucleotide polymorphism
(SNP) allelic discrimination by means of an ABI 7900HT
(Applied Biosystems, Foster City, CA, USA) in a 384-well for-
mat. The TaqMan Assay kit was purchased from Applied Bio-
systems (Foster City, CA, USA). Genotyping was performed
in a 5-mL volume containing 2.5 mL of TaqMan Universal
PCR Master Mix, 0.125 mL of 40= TaqMan MGB Assay Mix,
and 25 ng of genomic DNA. Primers of rs1333049 polymor-
phism were TCACTACCCTACTGTCATTCCTCAT and TTGC-
fjTTACCTCTGCGAGTGG. Probes were VIC-CAACAGTT-
CAAAAGCA and FAM-AACAGTTGAAAAGCA. Primers of
rs10757274 were CCCCCGTGGGTCAAATCTAAG and
AGAATTCCCTACCCCTATCTCCTATCT. Probes were VIC-
CTGAGTGTTGAGACATA and FAM-CTGAGTGTTGGGACA-
TA. Data were analyzed using the ABI Prism SDS software
version 2.1 (Applied Biosystems).
Statistical analysis
Continuous and categorical variables were expressed as
mean"SD and frequencies, respectively. Differences among
groups were assessed using the x2-test, Kruskal-Wallis H or
ANOVA. The x2-test for goodness of fit was used to verify
agreement with Hardy-Weinberg equilibrium. Cumulative
survival plots according to the genotype were evaluated
using univariately by Kaplan-Meier analysis (log-rank test).
Multivariate logistic analysis was performed to determine
independent factors for occurrence of MI. A 2-sided proba-
bility level of F0.05 was used for statistical significance. All
analyses were done with SPSS for Windows 13.0 (SPSS Inc,
Chicago, IL, USA).
Results
The genotype distribution in patients with MI and
controls was in Hardy-Weinberg equilibrium (all
p)0.05). In this study, we performed rs1333049 and
rs10757274 genotypes in 250 control subjects and
found they were in strong linkage disequilibrium
(r2s0.92). Therefore, rs1333049 was finally chosen in
the study.
Clinical characteristics of the controls and patients
with MI are shown in Table 1. Compared with con-
trols, patients with MI had more traditional risk factors
with higher fasting glucose, apoB, lipoprotein (a), and
creatinine concentrations and lower apoA or HDL-C
level (all p-0.01). No association of conventional risk
factors with rs1333049 was observed in patients or
controls.
Patients with MI had higher frequencies of the CC
genotype (30.0% vs. 20.7%) or C allele (55.5% vs.
46.2%) compared with controls (all p-0.01) using uni-
variate analysis (Table 1). Multivariate logistic regres-
sion analysis revealed that genotypes carrying allele
C were independent risk factors for MI after adjust-
ment for conventional risk factors wodds ratio (OR)
1.41, 95% confidence interval (CI) 1.17–1.70,
p-0.001x. Body mass index (BMI), triglyceride, total
cholesterol, low HDL-C, lipoprotein (a), and creatinine
were also found to be independent determinants for
MI (Table 2).
There was no significant difference in number of
diseased coronary arteries, lesion morphology, infarct
site, and stroke among the subgroups of rs1333049
genotype (Table 3). Also there was no difference in
LVEF, incidence of recurrence of non-fatal MI, recur-
rent angina, heart failure requiring hospitalization or
composite MACE among patients with varying geno-
types (Table 4). Cumulative survival rate was also
similar among the three genotypes (Figure 1).
Discussion
The present study demonstrated that rs1333049 poly-
morphism on chromosome 9p21 was associated with
MI, but not with angiographic severity of CAD and 2
years occurrence of MACE after MI in Han Chinese.
The Wellcome Trust Case Control Consortium iden-
tified an association of rs1333049 polymorphism
with CAD (p-10y14) in Caucasians (6). A later meta-
analysis revealed that genotypes carrying allele C
were associated with an increase of 24% (95%
CIs1.20–1.29) in risk for CAD. Our results showed
that the OR of allele C for MI was 1.41 (95% CI
1.17–1.70) after adjusting for conventional risk
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Table 2 Multivariate logistic regression analysis.
Risk factors OR p-Value 95% CI
BMI 0.93 0.006 0.89–0.98
Triglyceride 0.85 0.020 0.75–0.98
Total cholesterol 1.43 0.033 1.03–1.98
HDL-C 0.08 -0.001 0.05–0.15
LDL-C 0.86 0.432 0.60–1.25
Lipoprotein (a) 4.11 -0.001 1.91–8.83
Fasting glucose 1.04 0.281 0.97–1.12
Creatinine 1.02 -0.001 1.01–1.02
rs1333049 C allele 1.41 -0.001 1.17–1.70
OR, odds ratio; CI, confidence interval; BMI, body mass
index; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; MI, myocardial
infarction.
Table 4 Association of rs1333049 with clinical outcome after MI.
GG (ns99) GC (ns265) CC (ns156) p-Value
Treatment
Primary PCI, % 78.8 80.0 85.3 0.314
Aspirin, % 90.9 94.3 91.7 0.410
ACEI or ARB, % 67.7 64.9 62.8 0.730
b-Blocker, % 45.5 49.1 48.7 0.822
Statins, % 54.5 56.2 51.6 0.657
Duration, months 28"18 30"17 29"17 0.685
Adverse events
Rehospitalization, n 1"1 1"1 1"1 0.263
Death, % 2.0 1.1 2.6 0.537
Non-fatal MI, % 5.1 1.9 3.2 0.265
Combined MACE, % 48.8 49.7 51.2 0.940
Data are presented as mean"SD or percent. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; MACE, major adverse cardiac events; MI, myocardial infarction; PCI, percutanous coronary intervention.
Table 3 Association of rs1333049 with severity of MI at baseline.
GG (ns99) GC (ns265) CC (ns156) p-Value
Number of diseased arteries
F1 vessel disease, % 42.4 37.7 32.1
2 vessel disease, % 32.3 34.3 36.5 0.550
3 vessel disease, % 25.3 27.9 31.5
Number of significant stenoses, n 120 308 185 0.322
Morphology of significant lesions
Type A, % 12.5 17.9 14.1
Type B1, % 31.7 33.8 30.3
Type B2, % 37.5 35.9 34.6 0.221
Type C, % 18.3 12.4 21.1
Echocardiography
LVEF, % 56.3"9.1 57.5"8.1 56.5"9.3 0.608
Infarct site
Anterior MI, % 34.3 35.8 34.0 0.916
Inferior MI, % 48.5 40.8 41.0 0.384
Anteriorqinferior MI, % 12.1 17.0 16.7 0.447
Length of hospital stay, days 14"5 14"4 15"6 0.015
Anti-hypertension treatment, % 31.4 24.7 24.6 0.387
Statin treatment, % 5.9 9.5 9.1 0.536
Ischemic stroke history, % 13.1 11.3 10.3 0.780
Data are presented as mean"SD or percent. LVEF, left ventricular ejection fraction; MI, myocardial infarction.
factors, indicating the possible impact of rs1333049
polymorphism on CAD in Chinese.
In this study, rs1333049 polymorphism was not
associated with total number of diseased vessels or
morphology of lesions. These observations were in
line with the report by Anderson et al. (12), and sug-
gested that variants at the 9p21 locus may robustly
predict the prevalence of angiographic CAD, but not
angiographic CAD severity. Assimes et al. revealed
that chromosome 9p21 variation was associated with
total coronary plaque burden as expressed by calci-
fication scores (13). However, angiographic CAD
severity defined as number of stenotic coronary arter-
ies appeared to correlate weakly with atherosclerotic
plaque burden of the coronary tree.
Several prospective studies have shown that chro-
mosome 9p21 variation was associated with devel-
opment of atherosclerosis and incident cardio-
vascular disease (14–16). However, Chen et al.
revealed that 9p21 conferred null effects on the sever-
ity or progression of coronary atherosclerosis in Cau-
casians (17). Likewise, a recent report from the
Rotterdam cohort study did not show an association
of chromosome 9p21 with incidence of CAD or MI in
older individuals (18). In our study, no association
was observed between genotypes of rs1333049 poly-
morphism and occurrence of MACE after MI. These
results suggest that the predictive value of chromo-
some 9p21 for clinical outcomes in these patients
may not be sufficient, at least for Han Chinese. This
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Figure 1 Kaplan-Meier survival plot by rs1333049.
Cumulative survival rate was similar among the GG (ns99),
GC (ns265), and CC (ns156) genotypes.
may be explained by the lack of relation between
chromosome 9p21 polymorphism and left ventricular
function and severity of CAD; the latter two factors
were major determinants for prognosis in patients
with MI. Furthermore, medical or interventional
therapy could mitigate the influence of certain genetic
factors including rs1333049 polymorphism in cardio-
vascular disease. Finally, to a certain extent, optimiz-
ing lifestyle and proper control of risk factors would
weaken the genetic impact on atherosclerosis at the
individual level.
In multiple logistic regression analysis, we found
that serum creatinine was associated with MI in addi-
tion to rs1333049. Renal impairment may be a marker
for undiagnosed vascular disease or severity of vas-
cular damage. It is also possible that atherogenic
effects of traditional risk factors such as tobacco use,
hyperlipidemia, hypertension, and diabetes may be
greater in the presence of moderate to severe renal
failure, which could also contribute to an increase in
progression of CAD, MI and late mortality (19).
Some studies have probed the mechanisms behind
the associative effect of chromosome 9p21. The locus
on chromosome 9p21 spans about 50–60 kb, contain-
ing no protein coding gene. Nevertheless, existing
nearby is a cluster cell cycle promoting factor genes
including cyclin-dependent kinase inhibitors 2A and
2B (CDKN2A and CDKN2B). These play a significant
role in regulating cell proliferation, senescence and
apoptosis (20). It is possible that certain genetic vari-
ants in this region relate to the altered expression of
CDKN2A, CDKN2B, and/or other genes located nearby
(21, 22).
Conclusions
In summary, the rs1333049 polymorphisms on chro-
mosome 9p21 were associated with MI, but not
angiographic severity of CAD and did not affect MACE
rate during a 2-year follow-up in Han Chinese. Further
large studies are needed to clarify the role of the locus
at chromosome 9p21 in atherosclerosis and its
complications.
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